Obesity Abstracts

Background: Hyperglucagonaemia is one of the key players in the pathophysiology of type 2 diabetes. Roux-en-Y Gastric Bypass (RYGB) is currently a highly effective treatment for weight loss and diabetes remission. However, the role of glucagon in the above effects is unclear.Aim: To characterise the behaviour of proglucagon-derived peptides (glucagon, glucagon-like peptide-1, oxyntomodulin, glicentin) after RYGB surgery.Subjects an...

Background: Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy are two widely used bariatric procedures. Longitudinal data have shown similar efficacy in terms of sustained weight loss and diabetes remission in obese patients with type 2 diabetes. Altered glucose dynamics with increased glycaemic variability and the occurrence of hypoglycaemia are common post-bariatric surgery. Aim: To compare the glycaemic variability and incidence of hypoglycaemia ...

Until recently, only two medications were licenced and approved by the National Institute of Health and Care Excellence (NICE) for weight loss, orlistat and liraglutide. Semaglutide 2.4mg was launched in September 2023. Both liraglutide and semaglutide belong to a class of drugs called GLP-1 analogues, also used in the treatment of Type 2 diabetes. Successful weight loss outcomes for GLP-1 analogues has led to increased global demand and shortages. In June 2023, a National Pat...